We use press releases to update external stakeholders on our progress. We want to make sure you have all the information you need to provide comprehensive feedback on our reports.
Subscribers can expect to receive press releases at the following milestones: Topic Announcement, Draft Evidence Report, Revised Evidence Report, and Final Evidence Report.
You can also find the week’s press releases in our newsletter.
For any questions, please contact mediainquiries@icer.org.
Sign up for our Press Releases and Newsletter!
Featured Press Releases
ICER to Assess Treatment for Hypertrophic Cardiomyopathy
Report will be subject of CTAF meeting in October 2021; Draft Scoping Document open to public comment until April 29th, 2021
04/08/2021ICER Publishes Evidence Report on Therapies for Multiple Myeloma
The evidence suggests CAR-Ts ide-cel and cilta-cel both have the potential to help patients live substantially longer with manageable side effects, although ide-cel’s recently announced price would still require at least a 37% discount to reach ICER’s recommended health-benefit price benchmark. The evidence also suggests belantamab appears to be equivalent or slightly superior to alternative […]
04/05/2021ICER Analytics™ Launched to Accelerate the Real-World Application of ICER Reports, Helping Payers, the Life Science Industry, and Health Care Policy Makers Move From Insight to Action
ICER formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to develop formularies, negotiate drug prices.
11/30/2020